Clinical trials: Dermatitis Atopic
Atopic Dermatitis Eczema
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05935085
- Testing
- ANB032
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 201 people
- Sponsor
- AnaptysBio, Inc.
Moderate to Severe Atopic Dermatitis
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
- Trial name
- NCT06723080
- Testing
- VC005 low dose group, VC005 high dose group
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Severe Atopic Dermatitis (AD)
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe…
- Trial name
- BUILD-PEDS (NCT07187089)
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis
The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).
- Trial name
- Phoenix (NCT01691209)
- Testing
- Phoenix (BAY81-2996), 1% Hydrocortison cream
- Where
- Germany
- Sponsor
- Bayer
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- NCT03607422
- Testing
- Upadacitinib
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Asthma
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic…
- Trial name
- NCT00160563
- Testing
- LEVOCETIRIZINE
- Where
- 51 sites in Australia, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- UCB Pharma
Atopic Dermatitis
Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of autologous mesenchymal stem cells.
- Trial name
- NCT02888704
- Testing
- ADSTEM Inj. (Adult human mesenchymal stem cells)
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- EHL Bio Co., Ltd.
Atopic Dermatitis
Photocil (Topical) for the Treatment of Atopic Dermatitis
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight.
- Trial name
- NCT01992172
- Testing
- Photocil for Atopic Dermatitis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Applied Biology, Inc.
Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
- Trial name
- ROCKET-Ignite (NCT05398445)
- Testing
- Rocatinlimab
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Atopic Dermatitis
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03531957
- Testing
- ASN002
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 244 people
- Sponsor
- Asana BioSciences
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis
This Study Evaluate the efficacy of the subministration of fermented rice flour (7 g/day) on the clinical course of patients with moderate or severe Atopic Dermatitis, in terms of a reduction in the SCORAD score, during the study…
- Trial name
- NCT03157284
- Testing
- Rice Flour
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Heinz Italia SpA
Atopic Dermatitis, Eczema
Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to ointment base (vehicle) in subjects with Atopic Dermatitis (AD).
- Trial name
- NCT01359787
- Testing
- Mapracorat, Vehicle without active
- Where
- Germany
- Volunteers
- 197 people
- Sponsor
- Bayer
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Atopic Dermatitis
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement.
- Trial name
- NCT05127421
- Testing
- Ruxolitinib cream, Vehicle
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis (Eczema)
The Effects of a Botanical Moisturizer, an Oral Supplement, and an Unscented Soap on Eczema and Itch
The purpose of this study is to examine the effects of a botanical moisturizer, an oral supplement, and an unscented soap on eczema severity, itch, mood, and various skin measures (such as skin hydration) in those with mild to…
- Trial name
- NCT06819709
- Testing
- Botanical Moisturizer + Oral Supplement + Unscented Soap
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Codex Labs Corporation
Healthy Participants, Atopic Dermatitis Patients
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
- Trial name
- NCT06193434
- Testing
- IBI356 for MAD, Dupilumab for MAD, IBI356 for SAD
- Where
- China
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Psoriasis, Atopic Dermatitis
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
- Trial name
- NCT06005792
- Testing
- XmAb27564
- Where
- 7 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Xencor, Inc.
Atopic Dermatitis (AD)
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT07182864
- Testing
- MH004 0.1% Ointment, MH004 0.3% Ointment, MH004 1.0% Ointment
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.